ERBB2 and breast carcinoma: This work aimed to evaluate radiomics features to differentiate malignant versus benign lesions, to predict low versus moderate and high grading, to identify positive or negative hormone receptors, and to discriminate positive versus negative human epidermal growth factor receptor 2 related to breast cancer.